BIO
Bio-Rad Laboratories Inc
Bio-Rad Laboratories Inc historical holders
total: 5
Ariel Appreciation Fund Bio-Rad Laboratories Inc transactions over time
- Total transactions:
- 9
- New positions:
- 1
- Added:
- 5
- Reduced:
- 3
- Held since:
- 2024 Q1
- Held for:
- 9 quarters
- Latest activity:
- 2026 Q1
John W. Rogers Jr. has been an institutional investor in Bio-Rad Laboratories Inc (BIO) since 2024 Q1. According to 2026 Q1 report, John W. Rogers Jr. holds 80,900 shares with a market value of roughly $22.55M representing 2.58% of their equity portfolio. The fund/company first acquired BIO in 2024 Q1, initially purchasing 34,165 shares. Since the initial investment, Ariel Appreciation Fund has made 8 more transactions in this position.
Does John W. Rogers Jr. still hold BIO?
Yes, John W. Rogers Jr. continues to hold Bio-Rad Laboratories Inc (BIO). According to their 2026 Q1 report, they maintain a position of 80,900 shares valued at approximately $22.55M, representing 2.58% of their equity portfolio.
When did John W. Rogers Jr. first invest in BIO?
John W. Rogers Jr. first invested in Bio-Rad Laboratories Inc (BIO) in 2024 Q1 at the reported quarter-end price of $345.87 per share, acquiring 34,165 shares in their initial purchase.
What is John W. Rogers Jr.'s average cost basis for BIO?
Based on historical transaction data, John W. Rogers Jr.'s estimated cost basis for Bio-Rad Laboratories Inc (BIO) is approximately $309.71 per share. This represents their average reported price* across all buy transactions.
Estimated cost basis*
- Weighted AVG buy price:
- $309.71
- Weighted AVG sell price:
- $291.19
BIO transactions history by Ariel Appreciation Fund
9 results
| Period |
% of portfolio |
Shares held after* |
Reported price* |
Value* |
% (shares) of activity |
% change to portfolio |
|---|---|---|---|---|---|---|
|
2026 Q1
|
2.58%
|
80,900
|
$278.75
|
$22,550,875
|
-3.41% (-2,856)
|
-0.09%
|
|
2025 Q4
|
2.85%
|
83,756
|
$302.99
|
$25,377,230
|
-6.77% (-6,086)
|
-0.21%
|
|
2025 Q3
|
2.81%
|
89,842
|
$280.39
|
$25,190,798
|
-3.61% (-3,363)
|
-0.11%
|
|
2025 Q2
|
2.65%
|
93,205
|
$241.32
|
$22,492,231
|
+6.64% (+5,801)
|
+0.17%
|
|
2025 Q1
|
2.50%
|
87,404
|
$243.56
|
$21,288,118
|
+14.83% (+11,287)
|
+0.32%
|
|
2024 Q4
|
2.62%
|
76,117
|
$328.51
|
$25,005,196
|
+14.05% (+9,379)
|
+0.32%
|
|
2024 Q3
|
2.21%
|
66,738
|
$334.58
|
$22,329,200
|
+29.05% (+15,025)
|
+0.5%
|
|
2024 Q2
|
1.47%
|
51,713
|
$273.11
|
$14,123,337
|
+51.36% (+17,548)
|
+0.5%
|
|
2024 Q1
|
1.10%
|
34,165
|
$345.87
|
$11,816,649
|
new
|
+1.1%
|
* Shares, change to shares, sold shares, shares held after: split-adjusted.
* Reported price: this doesn't represent the actual buy or sell price. It is the split-adjusted price of the security as of the last day of the reported period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
* Estimated cost basis: based on "Reported price*" (not earlier than 2013 Q2). Calculation starts from the latest "new buy" activity to the latest "close out" activity (if any).
* Value or Price: If the security is completely sold out, we show the reported value (or price) prior to the actual period.
* New buy or own: this means there is no earlier reporting (for us or in general). So we can't know if the actual purchase of the security happened at the reported period or earlier.